肝移植病人术后他克莫司剂量的个体化调整  

Tacrolimus dosage individualization in patients after liver transplantation

作　　者：丁海[1] 端木浩[1] 易永祥[1] 吴岷岷[1] 刘俊卯[1] 叶正青[1] 梁重峰[1] 魏威[1] 

机构地区：[1]南京市第二医院外科,江苏南京210003

出　　处：《胃肠病学和肝病学杂志》2009年第8期757-759,共3页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目的了解肝移植后肝脏功能和血药浓度的共同检测对指导个体化抗排异减量的意义。方法动态随访检测15例肝移植病人肝功能与他克莫司(FK506)血药浓度,根据检测结果进行FK506剂量的个体化调整。结果15例病人在联合检测行FK506个体化的减量过程中均获得成功。结论肝移植病人术后,通过肝脏功能和FK506血药浓度的共同检测,可以指导抗排异药物达到合理、有效、个体化的调整使用,值得临床推广。Objective To investigate the role of combining of liver function test and blood Tacrolimus concentration measurement in the Tacrolimus dosage individualization in liver transplant recipients. Methods Fifteen patients of liver transplant who taking Tacrolimus were included. The Tacrolimus dosage was adjusted according to their liver function test and blood Tacrolimus concentration measurement. Results All 15 patients had received proper Tacrolimus dosage adjustment successfully. Conclusion Tacrolimus dosage adjustment for liver transplant recipients can be directed by the combining use of their liver function test and the measurement of blood Tacrolimus concentration. It has more advantage than use of the dosage/blood concentrations ratio to adjust dosage and also helps to reduce patient＇ s economic burden.

关 键 词：肝移植 他克莫司 肝功能 个体化 

分 类 号：R979.5[医药卫生—药品]